Cannabinoids for spasticity in severe cerebral palsy in children: double-blind RCT

Introduction and clinical context

The study Cannabinoids for spasticity in severe cerebral palsy in children: double-blind RCT (PubMed · 2024) is part of the scientific research on the use of cannabinoids in pediatrics.

In pediatrics, medical cannabis is studied for spasticity in cerebral palsy, symptom control in oncology and palliative care, and complex motor disorders. Studies report an improvement in symptoms and quality of life in some cases, with an acceptable tolerability profile, but not always statistical superiority over placebo. Use in children requires careful indication, adjusted doses and specialized follow-up.

Understanding what science shows about the use of cannabinoids in pediatrics helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Double-blind RCT (53 children/adolescents, CBD:THC 10:1): well tolerated and safe; no significant spasticity difference vs placebo. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In pediatrics, prescribing cannabinoids requires redoubled care: the developing brain is more sensitive to THC's effects, which is why CBD-rich formulations are favored in many indications. The mechanisms involve the modulation of neuronal excitability, spasticity and symptoms such as pain and nausea. Safety requires weight-adjusted doses, slow titration and monitoring of drowsiness, appetite changes and interactions. Use should be careful, led by a specialized team and integrated into overall pediatric care.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2024). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Is cannabis used in children?

In specific indications and under specialized follow-up, with adjusted doses and careful indication.

Is there proof of efficacy?

There are reports of symptomatic improvement, but not always statistical superiority over placebo.